Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

289.03
Delayed Data
As of 3:59pm ET
 +0.68 / +0.24%
Today’s Change
223.02
Today|||52-Week Range
338.51
-5.65%
Year-to-Date
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
10:07am / Zacks.com - Paid Partner Content
5 Undervalued Growth Stocks to Buy Today
Jul 27 / MotleyFool.com - Paid Partner Content
Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View
8:40am / Zacks.com - Paid Partner Content
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Jul 27 / Zacks.com - Paid Partner Content
Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short
7:51am / Zacks.com - Paid Partner Content
Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure
Jul 27 / TheStreet.com - Paid Partner Content
2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
7:31am / Zacks.com - Paid Partner Content
5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
Jul 26 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Jul 27 / Zacks.com - Paid Partner Content
An Investing Overview of the Multiple Sclerosis Market
Jul 26 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close288.35
Today’s open288.99
Day’s range285.07 - 289.98
Volume1,453,572
Average volume (3 months)1,841,347
Market cap$63.2B
Dividend yield--
Data as of 3:59pm ET, 07/28/2016

Growth & Valuation

Earnings growth (last year)+24.01%
Earnings growth (this year)+16.67%
Earnings growth (next 5 years)+9.50%
Revenue growth (last year)-3.87%
P/E ratio16.9
Price/Sales7.60
Price/Book6.73

Competitors

 Today’s
change
Today’s
% change
BAXBaxter International...-0.10-0.21%
GILDGilead Sciences-0.55-0.67%
NBIXNeurocrine Bioscienc...-0.67-1.32%
JUNOJuno Therapeutics In...-0.46-1.51%
Data as of 4:01pm ET, 07/28/2016

Financials

Last reporting dateJuly 21, 2016
EPS forecast (this quarter)$4.68
Annual revenue (last year)$9.3B
Annual profit (last year)$3.5B
Net profit margin38.05%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
George A. Scangos
Chief Scientific Officer &
Executive VP
Spyridon Artavanis-Tsakonas
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers

Search for Jobs